Trimethadione is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments. Trimethadione (TMO) has the properties required of probe drugs for the evaluation of hepatic drug-oxidizing capacity in humans in vivo. TMO is demethylated to dimethadione (DMO), its only metabolite, in the liver after orally bioavailable administration. References: Pastore V, Wasowski C, Higgs J, Mangialavori IC, Bruno-Blanch LE, Marder M. A synthetic bioisoster of trimethadione and phenytoin elicits anticonvulsant effect, protects the brain oxidative damage produced by seizures and exerts antidepressant action in mice. Eur Neuropsychopharmacol. 2014 Aug;24(8):1405-14. doi: 10.1016/j.euroneuro.2014.04.005. Epub 2014 May 2. PubMed PMID: 24846538.

纯度：≥98%

CAS：127-48-0